Mon, 26 Oct 2026 08:00:00 -0400 · 17 days ago Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity
Tue, 20 Oct 2026 08:30:00 -0400 · 23 days ago Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia
Tue, 29 Sep 2026 07:30:00 -0400 · 6 weeks ago Optimi Health Appoints Melanie Pump to Board of Directors
Wed, 23 Sep 2026 09:00:00 -0400 · 7 weeks ago Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
Tue, 22 Sep 2026 09:00:00 -0400 · 7 weeks ago Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
Wed, 16 Sep 2026 08:25:00 -0400 · 1 month ago Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
2026-09-10T14:25:37.000Z · 2 months ago Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD
Thu, 10 Sep 2026 08:45:00 -0400 · 2 months ago Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
Tue, 08 Sep 2026 08:30:00 -0400 · 2 months ago Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Fri, 14 Aug 2026 16:55:00 -0400 · 3 months ago Optimi Health Establishes Discretionary Equity Facility
Mon, 29 Jun 2026 09:00:00 -0400 · 4 months ago Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
2026-06-16T16:41:01.000Z · 4 months ago Optimi launches standardized microdose psilocybin products for clinical research
Tue, 16 Jun 2026 08:30:00 -0400 · 4 months ago Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
2026-06-11T14:20:25.000Z · 5 months ago Psychedelic: Optimi Health completes psilocybin export to the UK IXHL MIRA NRXP
2026-06-10T13:24:34.000Z · 5 months ago Optimi Health completes first export of naturally derived psilocybin to the UK
Wed, 10 Jun 2026 09:15:00 -0400 · 5 months ago Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
2026-06-08T17:01:01.000Z · 5 months ago Optimi Health commences finished ibogaine drug product development
Mon, 08 Jun 2026 08:00:00 -0400 · 5 months ago Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
2026-06-02T14:57:10.000Z · 5 months ago Optimi Health completes commercial production of psilocybin capsules
Tue, 02 Jun 2026 07:30:00 -0400 · 5 months ago Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
2026-05-29T13:55:45.000Z · 5 months ago Optimi Health reports expanded psychedelic-assisted therapy access in Australia
Fri, 29 May 2026 08:30:00 -0400 · 5 months ago Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
2026-05-28T16:52:34.000Z · 5 months ago Psychedelic: Optimi Health advances natural psilocybin extract CMND CMPS MIRA NRXP
Wed, 27 May 2026 08:00:00 -0400 · 5 months ago Diamond Equity Research Initiates Coverage on Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN)
Tue, 26 May 2026 07:00:00 -0400 · 5 months ago Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date
Thu, 21 May 2026 13:07:00 -0400 · 5 months ago Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
Thu, 21 May 2026 09:00:00 -0400 · 5 months ago SRx Health Solutions and EMJX Invest in Recent IPO and Commercial-Stage Pharmaceutical Company of Psychedelics, Optimi Health Corp. (OPTH)
Wed, 20 May 2026 08:00:00 -0400 · 5 months ago Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
Apr 23, 2026, 7:00 AM EDT · 6 months ago Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing
Apr 20, 2026, 6:00 AM EDT · 6 months ago Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
Mar 16, 2026, 7:00 AM EDT · 8 months ago Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering
Feb 26, 2026, 7:00 AM EST · 8 months ago Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
Feb 19, 2026, 2:00 AM EST · 8 months ago Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression
Jan 26, 2026, 7:00 AM EST · 9 months ago Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules